Kazia Therapeutics Ltd · NASDAQ:KZIA

Kazia Therapeutics — Investor Presentation (October 2020)

35 slides from Kazia Therapeutics's investor presentation, Oct 1, 2020

  1. Slide 1: Kazia Investor Presentation (ASX Release)

    ASX RELEASE 1 October 2020 Not for release to US newswire services or distribution in the United States KAZIA INVESTOR PRESENTATION Sydney, 1 October 2020 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide a copy of its

  2. Slide 2: Non-Renounceable Entitlement Offer to Shareholders

    NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES Non-Renounceable Entitlement Offer to Shareholders Investor Presentation 1 October 2020 ASX: KZA | NASDAQ : KZIA | Twitter: @KaziaTx

  3. Slide 3: Corporate Overview

    Corporate Overview Oncology-focused, mid-clinical-stage, small-molecule Company biotechnology company, headquartered in Sydney, Description Australia Paxalisib – brain-penetrant PI3K / mTOR inhibitor about to enter international phase III for glioblastoma Pipeline Cantrixil – cancer stem cell-target

  4. Slide 4: Chairman's Introduction

    Chairman’s Introduction Dear Fellow Shareholders, Our company stands poised to commence the GBM AGILE pivotal study for the registration of our lead program, paxalisib. This is an exciting place to be for any biotech company, and it will launch Kazia on a direct path to commercialisation of this tre

  5. Slide 5: Overview of the Offer

    Overview of the Offer A1 for 3 accelerated pro-rata non-renounceable entitlement offer to raise approximately A$25 OFFER STRUCTURE million (Entitlement Offer) via the issue of approximately 31.5 million new ordinary shares (New Shares). All New Shares under the Entitlement Offer will be issued at A$

  6. Slide 6: Use of Funds

    Use of Funds Proceeds of the Offer will be used to fund Kazia’s participation in GBM AGILE, the pivotal study for registration of paxalisib in glioblastoma, and for general working capital to the company Timing of Deployment • Kazia anticipates execution of a definitive agreement to operationalise G

  7. Slide 7: Investment Rationale

    Investment Rationale • Paxalisib developed by Genentech, the world’s most successful cancer drug company • Well-proven mechanism of action, with unique differentiating factor of brain penetration World-Class Asset in • Strong scientific rationale for development in brain cancer Brain Cancer • Encour

  8. Slide 8: Entitlement Offer Timetable

    Entitlement Offer Timetable KZA placed in trading halt on ASX Wednesday 30 September 2020 Institutional Entitlement Offer opens Thursday 1 October 2020 Institutional Entitlement Offer closes Thursday 1 October 2020 Trading halt lifted – shares recommence trading on ASX on an “ex-entitlement” basis F

  9. Slide 9: Program Overview

    Program Overview 7

  10. Slide 10: Treatment of brain cancer has improved little in recent decades

    Treatment of brain cancer has improved little in recent decades, unlike other cancers Brain Cancer 1990s 2000s 2010s (glioblastoma) Lung 1990s 2000s 2010s Cancer 8

  11. Slide 11: Paxalisib was designed to overcome brain cancer treatment challenges

    Paxalisib was designed specifically to overcome challenges associated with brain cancer treatment Challenge Approach Commercially Attractive Blood-Brain Barrier Brain-Penetration • Composition of matter Most cancer therapies do not GDC-0084 is designed to cross the patents through to 2031 penetrate

  12. Slide 12: The PI3K class is well-established, but paxalisib crosses the blood-brain barrier

    The PI3K class is well-established, but paxalisib is unique in its ability to cross the blood-brain barrier Zydelig (idelalisib) Aliqopa (copanlisib) Copiktra (duvelisib) Piqray (alpelisib) paxalisib FDA Approved FDA Approved FDA Approved FDA Approved In phase II human trials July 2014 ✓ September 2

  13. Slide 13: Glioblastoma is the most common and aggressive primary brain cancer

    Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung No clear 3-4 months 12-15 cause untreated months Breast or strong risk survival average 14 million factors survival with cancer cases treatment per annum Colon Any age, Five-year Prostate but most survival co

  14. Slide 14: Temozolomide is the only FDA-approved GBM drug; ineffective in ~65%

    Temozolomide is only FDA-approved drug for GBM; it is ineffective in ~65% of cases Standard of Care Debulking surgery Radiotherapy + Temozolomide (‘Stupp where possible temozolomide maintenance therapy Regimen’) 6 weeks 4w 6 x 28-day cycles ~35% of patients respond Paxalisib is being developed for t

  15. Slide 15: Ongoing phase II study focuses on newly-diagnosed patients

    The ongoing phase II study is designed to focus on newly-diagnosed patients, following radiotherapy Step 1: Dose Optimisation Step 2: Expansion Cohort 9 patients 21 patients • Newly-diagnosed September 2018 – May 2019 June 2019 – February 2020 patients with the unmethylated MGMT promotor (i.e. resis

  16. Slide 16: New phase II data compares favourably to temozolomide

    New phase II data compares favourably to historical data for temozolomide (existing standard of care) Progression-Free Survival (PFS) Overall Survival (OS) Part A + Part B (n=30) Part A (n=9) Paxalisib 8.5 months Paxalisib 17.7 months Median PFS Median OS Existing 5.3 months Existing 12.7 months The

  17. Slide 17: A broad-based clinical program across multiple forms of brain cancer

    A broad-based clinical program is underway across multiple forms of brain cancer Paxalisib (GDC-0084) Primary Brain Cancer Secondary Brain Cancer (brain cancer that begins in the brain) (brain cancer that spreads from elsewhere in the body) Glioblastoma Glioblastoma DIPG Primary CNS Brain Breast Bra

  18. Slide 18: GBM AGILE is the planned pivotal study for paxalisib

    GBM AGILE is the planned pivotal study for paxalisib in glioblastoma What is GBM AGILE? Who is Behind It? • A ‘platform study’, designed by the leading experts in brain cancer to GBM AGILE is sponsored by the Global expedite the approval of new drugs for glioblastoma Coalition for Adaptive Research

  19. Slide 19: GBM AGILE is an adaptive multi-drug registrational study

    GBM AGILE is an adaptive multi-drug registrational study, with strong FDA support Drug #1 3 Economies of scale Randomization Drug #2 due to multiple 2 participating drugs allows for large site Comparison against pool, robust study Drug #3, etc… a common control infrastructure, and arm reduces overal

  20. Slide 20: GBM AGILE addresses key challenges faced by small biotechs

    GBM AGILE directly addresses the key challenges faced by small biotechs and their investors Challenge Approach Indicative Parameters Limited Funding More Cost-Effective Approach • Primary patient population Many biotech companies cannot AGILE achieves huge efficiencies, and essentially identical to

  21. Slide 21: Recent regulatory achievements position paxalisib for commercialisation

    Recent regulatory achievements position paxalisib well as it moves towards commercialisation Glioblastoma DIPG Advantages to Kazia Most common and most Highly aggressive childhood • ‘Data exclusivity’ provides additional aggressive form of brain brain cancer protection against competition cancer bey

  22. Slide 22: Brain cancer is a significant commercial opportunity with limited competition

    INDICATIVE Brain cancer represents a significant commercial opportunity for paxalisib, with limited competition Path to Market Expansion Opportunities ‘Blue Sky’ Potential Brain Metastases Glioblastoma (secondary brain cancer) Other Adult Other Cancers with Primary Brain Disordered PI3K 12,500 Cance

  23. Slide 23: Positive newsflow has supported revaluation of Kazia

    Positive newsflow has supported revaluation of Kazia as paxalisib moves towards commercialisation Share Price (AU$) KZA 1.20 Market Capitalisation ~AU$ 90 million 1.00 Shares on Issue ~94 million ASX: KZA Listing NASDAQ: KZIA (1:10 ratio) 0.80 Hyecorp 17% (SYD family office) 0.60 Platinum Asset Mgmt

  24. Slide 24: Key Milestones and Anticipated Newsflow

    Key Milestones and Anticipated Newsflow Execution of definitive agreement with GCAR for GBM AGILE pivotal study October 2020 Further interim data from Kazia phase II glioblastoma trial November 2020 Initial interim data from phase I DIPG trial at St Jude November 2020 Initial interim data from phase

  25. Slide 25: A strong team with big pharma and biotech experience

    A strong team brings international experience in big pharma and early-stage biotech Board Scientific Advisory Board Iain Ross Professor Sir Murray Brennan Chairman Emeritus Chairman of Cancer Surgery at Memorial Sloan Kettering Executive and Board roles in pharma Hospital, New York and small biotech

  26. Slide 26: Appendices

    Appendices 24

  27. Slide 27: Important Notice (1/3)

    IMPORTANT NOTICE (1/3) This investor presentation (Presentation) has been prepared by Kazia Therapeutics Limited (ACN 063 259 754) (Kazia or Company) in relation to an accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Kazia (New Shares) under section 708AA of the Co

  28. Slide 28: Important Notice (2/3)

    IMPORTANT NOTICE (2/3) Readers or recipients of this Presentation should, before making any decisions in relation to their investment or potential investment in Kazia, consider the appropriateness of the information having regard to their own objectives and financial situation and seek their own pro

  29. Slide 29: Important Notice (3/3)

    IMPORTANT NOTICE (3/3) Financial information All references to dollars, cents or $ in this Presentation are to Australian currency, unless otherwise stated. Unless otherwise noted, all references to financial information are presented as at the full financial year ended 30 June 2020. Past performanc

  30. Slide 30: Risks of the Investment

    RISKS OF THE INVESTMENT COMPANY RISKS Not all drugs at this stage of development reach market. Pivotal clinical studies can demonstrate an unexpected lack of efficacy, or a previously unknown safety concern. Across Technical Success is Uncertain all drugs in development, the probability of a drug in

  31. Slide 31: Risks of the Investment

    RISKS OF THE INVESTMENT COMPANY RISKS The company depends on being able to attract and retain personnel with specialist expertise, Kazia is Dependent on Key and to ensure continuity of key management. The loss of one or more key members of the Personnel management team could material affect Kazia’s

  32. Slide 32: Risks of the Investment

    RISKS OF THE INVESTMENT OFFER RISKS The rights entitlement structure offers eligible existing shareholders the ability to apply for Demand May Exceed new shares pro rata, and any such applications will be met. The ability of the company to Availability of Stock meet applications by new shareholders

  33. Slide 33: Risks of the Investment

    RISKS OF THE INVESTMENT MARKET RISKS There are risks associated with investment in any company listed on the ASX, which include Investment in Public Equities both the financial and operational performance of the company and external factors outside Carries Inherent Risk the company’s control, such a

  34. Slide 34: International Offer Restrictions

    INTERNATIONAL OFFER RESTRICTIONS This document does not constitute an offer of new ordinary shares (New Shares) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any c

  35. Slide 35: www.kaziatherapeutics.com

    www.kaziatherapeutics.com

Kazia Therapeutics — Investor Presentation (October 2020) on 6ix